Bempedoic acid for the treatment of hypercholesterolemia

References

• Lorenzatti AJ, Toth PP. New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol. 2020;15:1–9.
   PubMed Web of Science ®Google Scholar
• Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics-2017 update: a report from the American heart association. Circulation. 2017;135(10):e146–e603.
   PubMed Web of Science ®Google Scholar
• Weng W, Tian Y, Kong SX, et al. Impact of atherosclerotic cardiovascular disease on healthcare resource utilization and costs in patients with type 2 diabetes mellitus in a real-world setting. Clin Diabetes Endocrinol. 2020;6(5). DOI:10.1186/s40842-019-0090-y.
   PubMedGoogle Scholar
• McManus R, Constanti M, Floyd CN, et al. Managing cardiovascular disease risk in hypertension. Lancet. 2020;395(10227): 869.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European atherosclerosis society consensus panel. Eur Heart J. 2017;38: 2459–2.
   Web of Science ®Google Scholar
• Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet. 2010;375(9729): 1875–4. DOI:10.1016/S0140-6736(10)60656-3.
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med. 2011;365(24):2255–2257.
   PubMed Web of Science ®Google Scholar
• Stein EA, Raal FJ. Lipid -lowering drug therapy for CVD prevention: looking into the future. Curr Cardiol Rep. 2015;17(11):104.
   PubMed Web of Science ®Google Scholar
• Vrablík M. Current and future trends in the treatment of dyslipidemias. Vnitr Lek. 2019;65(10): 643.
   PubMedGoogle Scholar
• Sirtori CR, Yamashita S, Greco MF, et al. Recent advances in synthetic pharmacotherapies for dyslipidaemias. Eur J Prev Cardiol. 2019 May 6. [ Epub ahead of print]. DOI: 10.1177/2047487319845314.
   Web of Science ®Google Scholar
• U.S.Food and Drug Administration. NEXLETOL (bempedoic acid) tablets, for oral use. [ cited 2020 March 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/211616s000lbl.pdf
   Google Scholar
• Ray KK, Corral P, Morales E, et al. Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options. Lancet. 2019;394(10199):697–698..
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Perrot N, Puri R. Therapeutic agents targeting cardiometabolic risk for preventing and treating atherosclerotic cardiovascular diseases. Clin Pharmacol Ther. 2018;104(2):257–258.
   PubMed Web of Science ®Google Scholar
• Banach M, Rizzo M, Toth PP, et al. Statin intolerance: an attempt at a unified definition. Position paper from an international lipid expert panel. Expert Opin Drug Saf. 2015;14: 935–5.
   PubMed Web of Science ®Google Scholar
• Banach M, Mikhailidis DP. Statin intolerance: some practical hints. Cardiol Clin. 2018;36(2):225–231.
   PubMed Web of Science ®Google Scholar
• Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37: 2999–8.
   Web of Science ®Google Scholar
• Polychronopoulos G, Tziomalos K. Novel treatment options for the management of heterozygous familial hypercholesterolemia. Expert Rev Clin Pharmacol. 2017;10(12): 1375–1.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Cannon CP, Blazing MA, et al. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved reduction of outcomes: vytorin efficacy international trial). Circulation. 2018;137(2):1571–1572..
   PubMedGoogle Scholar
• U.S.Food and Drug Administration. Zetia (ezetimibe) tablets. [ cited 2020 March 20]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21445lbl.pdf
   Google Scholar
• Rosenson RS, Hegele RA, Koenig W. Cholesterol-lowering agents. Circ Res. 2019;124(3):364–365.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18): 1713–2. DOI:10.1056/NEJMoa1615664.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22): 2097–7. DOI:10.1056/NEJMoa1801174.
   Web of Science ®Google Scholar
• Board C, Kelly MS, Shapiro MD, et al. PCSK9 inhibitors in secondary prevention - an opportunity for personalized therapy. J Cardiovasc Pharmacol. 2020 Feb 14. [ Epub ahead of print]. DOI: 10.1097/FJC.0000000000000809.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Newton RS, Ea D, et al. Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis. Nature Commun. 2016;7:13457.
   PubMed Web of Science ®Google Scholar
• Lemus HN, Mendivil CO. Adenosine triphosphate citrate lyase: emerging target in the treatment of dyslipidemia. J Clin Lipidol. 2015 May-Jun;9(3):384–389..
   PubMed Web of Science ®Google Scholar
• Barter PJ, Rye KA. New era of lipid-lowering drugs. Pharmacol Rev. 2016;68(2): 458–5.
   PubMed Web of Science ®Google Scholar
• Turner T, Stein EA. Non-statin treatments for managing LDL cholesterol and their outcomes. Clin Ther. 2015;37(12):2751–2759.
   PubMed Web of Science ®Google Scholar
• Bove M, Cicero AFG, Borghi C. Emerging drugs for the treatment of hypercholesterolemia. Expert Opin Emerg Drugs. 2019;24(1):63–69.
   PubMed Web of Science ®Google Scholar
• Nikolic D, Mikhailidis DP, Davidson MH, et al. ETC-1002: a future option for lipid disorders? Atherosclerosis. 2014;237(2):705..
   PubMed Web of Science ®Google Scholar
• Feng X, Zhang L, Xu S, et al. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: an updated review. Prog Lipid Res. 2020;77:101006.
   PubMed Web of Science ®Google Scholar
• Pinkosky SL, Filippov S, Srivastava RA, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013;54(1): 134–1. DOI:10.1194/jlr.M030528.
   Web of Science ®Google Scholar
• Bazilevsky GA, Affronti HC, Wei X, et al. ATP-citrate lyase multimerization is required for coenzyme-A substrate binding and catalysis. J Biol Chem. 2019;294(18): 7259–8. DOI:10.1074/jbc.RA118.006685.
   PubMed Web of Science ®Google Scholar
• Burke AC, Telford DE, Huff MW. Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 2019;30(1):1–9.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Davidson MH, Macdougall DE, et al., Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. J Am Coll Cardiol. 2013;62(13): 1154–2. DOI: 10.1016/j.jacc.2013.05.050.
   PubMed Web of Science ®Google Scholar
• Thompson PD, Rubino J, Janik MJ, et al., Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance. J Clin Lipidol. 2015;9(3): 295–4. DOI: 10.1016/j.jacl.2015.03.003.
   Web of Science ®Google Scholar
• Lalwani ND, Hanselman JC, MacDougall DE, et al., Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. J Clin Lipidol. 2019;13(4):568–569..
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, McKenney JM, MacDougall D, et al., Effect of ETC-1002 on serum low-density lipoprotein cholesterol in hypercholesterolemic patients receiving statin therapy. Am J Cardiol. 2016;117(12): 1928–3. DOI: 10.1016/j.amjcard.2016.03.043.
   PubMed Web of Science ®Google Scholar
• Gutierrez MJ, Rosenberg NL, Macdougall DE, et al., Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol. 2014;34(3): 676–3. DOI: 10.1161/ATVBAHA.113.302677.
   PubMed Web of Science ®Google Scholar
• Laufs U, Banach M, Mancini GBJ, et al., Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Assoc. 2019;8(7):e011662..
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Leiter LA, Stroes ESG, et al., Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR wisdom randomized clinical trial. JAMA. 2019;322(18):1780–1788..
   PubMed Web of Science ®Google Scholar
• Ray KK, Bays HE, Catapano AL, et al., Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380(11): 1022–2. DOI: 10.1056/NEJMoa1803917.
   Web of Science ®Google Scholar
• Ballantyne CM, Laufs U, Ray KK, et al. Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy. Eur J Prev Cardiol. 2020;27(6): 593–3.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Banach M, Mancini GBJ, et al. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study. Atherosclerosis. 2018;277: 195–3. DOI:10.1016/j.atherosclerosis.2018.06.002.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Nilemdo (bempedoic acid): EU summary of product characteristics. [ cited 2020 May 25]. Available from: http://attach.pubtsg.com:8088/attach/show?query=DwQ5T1dqLwtQi_so8lU8HsXhRqYG1W55EeunqUYAv46XYW6h5flu6eoA2FeC7NhA&view=true&type=.pdf
   Google Scholar
• European Medicines Agency. Nilemdo (bempedoic acid): EU summary of product characteristics. [ cited 2020 May 25]. Available from: https://ec.europa.eu/health/documents/community-register/html/h1424.htm
   Google Scholar
• Guadamuz JS, Durazo-Arvizu RA, Daviglus ML, et al. Citizenship status and the prevalence, treatment, and control of cardiovascular disease risk factors among adults in the United States, 2011–2016. Circ Cardiovasc Qual Outcomes. 2020;13(3):e006215..
   PubMed Web of Science ®Google Scholar
• Ajufo E, Rader DJ. New therapeutic approaches for familial hypercholesterolemia. Annu Rev Med. 2018;69: 113–1.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Tsimikas S. Lipid-lowering agents. Circ Res. 2019;124(3): 386–4.
   Web of Science ®Google Scholar
• Filippov S, Pinkosky SL, Newton RS. LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase. Curr Opin Lipidol. 2014;25:309e315.
   Web of Science ®Google Scholar
• Honigberg MC, Natarajan P. Bempedoic acid for lowering LDL cholesterol. JAMA. 2019;322(18): 1769–1.
   PubMed Web of Science ®Google Scholar
• Cicero AFG, Pontremoli R, Fogacci F, et al. Effect of bempedoic acid on serum uric acid and related outcomes: a systematic review and meta-analysis of the available phase 2 and phase 3 clinical studies. Drug Saf. 2020 May 1. [Epub ahead of print]. DOI: 10.1007/s40264-020-00931-6.
   PubMed Web of Science ®Google Scholar
• Zagelbaum NK, Yandrapalli S, Nabors C, et al. Bempedoic acid (ETC-1002): ATP citrate lyase inhibitor: review of a first-in-class medication with potential benefit in statin-refractory cases. Cardiol Rev. 2019;27(1): 49–6. DOI:10.1097/CRD.0000000000000218.
   PubMed Web of Science ®Google Scholar